How to Treat Carbapenem-Resistant Acinetobacter baumannii Infections: Current Knowledge and Personal Viewpoints.

Acinetobacter baumannii, particularly carbapenem-resistant strains (CRAB), represents a critical global health threat due to its multidrug resistance and association with severe healthcare-associated infections. Treatment options remain limited, with high mortality rates observed in ventilator-associated pneumonia (VAP), bloodstream infections (BSI), and central nervous system (CNS) infections. Colistin-based regimens, despite toxicity and pharmacokinetic limitations, have long been standard therapy. Recent therapeutic advances include cefiderocol and sulbactam/durlobactam, which show potential activity, especially when used in combination regimens.